Scarica l'app Stockscreener
2.62
1.87%
-0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.67
Aprire:
$2.66
Volume 24 ore:
7.82M
Relative Volume:
1.30
Capitalizzazione di mercato:
$1.91B
Reddito:
$1.31M
Utile/perdita netta:
$-597.65M
Rapporto P/E:
-2.2982
EPS:
-1.14
Flusso di cassa netto:
$-425.62M
1 W Prestazione:
-8.71%
1M Prestazione:
-46.26%
6M Prestazione:
-59.69%
1 anno Prestazione:
-42.16%
Intervallo 1D:
$2.61
$2.7065
Intervallo di 1 settimana:
$2.61
$3.18
Portata 52W:
$2.61
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Confronta IBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.62 | 1.91B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Immunitybio Inc Borsa (IBRX) Ultime notizie
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio (NASDAQ:IBRX) Sets New 1-Year LowShould You Sell? - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.6%Here's Why - MarketBeat
ImmunityBio: Forging A New Plan After Recent $100 Million Offering - Seeking Alpha
ImmunityBio Shares Plunge After Share Offering - Los Angeles Business Journal
ImmunityBio (NASDAQ:IBRX) Hits New 52-Week LowShould You Sell? - MarketBeat
ImmunityBio: Despite Share Price & Funding Woes Muddy Path To Long-Term Success (IBRX) - Seeking Alpha
ImmunityBio stock plummets on announcing common stock offering - MSN
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering - Yahoo Finance
Form 424B5 ImmunityBio, Inc. - StreetInsider.com
SEC Form 424B5 filed by ImmunityBio Inc. - Quantisnow
ImmunityBio announces proposed public offering of common stock - MSN
ImmunityBio’s Cash Burn And Dilution Dampen Anktiva’s Potential (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Shares Slide 33% After Public Offering Prices - MarketWatch
What's Going On With ImmunityBio Shares Wednesday? - Benzinga
IMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc.IBRX - The Eastern Progress Online
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock - Business Wire
ImmunityBio Shares Down on Plans for Public Offering - MarketWatch
ImmunityBio plans public stock offering By Investing.com - Investing.com Canada
ImmunityBio plans public stock offering - Investing.com India
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock - Business Wire
Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move - MSN
More layoffs for ImmunityBio's Dunkirk facility - MSN
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment - The Eastern Progress Online
(IBRX) Investment Analysis - Stock Traders Daily
ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
ImmunityBio and nCartes partner to automate clinical trial data processes - Clinical Trials Arena
Town hopeful after ImmunityBio tour - Evening Observer
Town Hopeful After ImmunityBio Tour - Jamestown Post Journal
ImmunityBio partners with nCartes to streamline trials - Investing.com
ImmunityBio and nCartes Enter Collaboration Agreement on Clinica - GuruFocus.com
ImmunityBio, nCartes announce collaboration on clinical trial data fulfillment - TipRanks
ImmunityBio partners with nCartes to streamline trials By Investing.com - Investing.com UK
ImmunityBio Partners with nCartes to Revolutionize Clinical Trial Data Management | IBRX Stock News - StockTitan
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet - MSN
Immunitybio Inc earnings beat by $0.04, revenue topped estimates - Investing.com Nigeria
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months - BioSpace
ImmunityBio announces new data from QUILT 3.032 study - TipRanks
ImmunityBio's Bladder Cancer Drug Shows 71% Response Rate in Key Trial | IBRX Stock News - StockTitan
Following recent decline, ImmunityBio, Inc.'s (NASDAQ:IBRX) top shareholder Chief Scientific Officer Patrick Soon-Shiong sees holdings value drop by 11% - Simply Wall St
ImmunityBio Inc. Reports Earnings Amid Financial Challenges - TipRanks
ImmunityBio Inc (IBRX) Q3 2024 Earnings: GAAP EPS of -$0.12, Rev - GuruFocus.com
ImmunityBio: Q3 Earnings Snapshot - The Pioneer
ImmunityBio Inc. (IBRX) Quarterly 10-Q Report - Quartzy
Innovative Bladder Cancer Therapy Produces $6 Million in Sales - Precision Vaccinations
ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunitybio Inc Azioni (IBRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Adcock Richard | CEO & President |
Feb 05 '24 |
Option Exercise |
0.00 |
83,334 |
0 |
286,303 |
| Simon Barry J. | Director |
Jan 31 '24 |
Option Exercise |
0.00 |
57,200 |
0 |
3,145,855 |
| Sachs David C. | Chief Financial Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
70,745 |
0 |
212,673 |
| LAUER REGAN J | Chief Accounting Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
32,872 |
0 |
107,804 |
| Sachs David C. | Chief Financial Officer |
Dec 31 '23 |
Option Exercise |
0.00 |
30,397 |
0 |
152,439 |
| Adcock Richard | CEO & President |
Dec 31 '23 |
Option Exercise |
0.00 |
34,483 |
0 |
220,065 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):